Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on October 9, 2006

Circulation. 2006
Published online before print October 9, 2006, doi: 10.1161/CIRCULATIONAHA.106.638395
A more recent version of this article appeared on October 17, 2006
This Article
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Circulation: October 17, 2006, Volume 114, Number 16
Right arrow All Versions of this Article:
114/16/1676    most recent
CIRCULATIONAHA.106.638395v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Da Costa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Da Costa, A.
Related Collections
Right arrow Ablation/ICD/surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrowRelated Article

Submitted on May 6, 2006
Revised on July 14, 2006
Accepted on July 21, 2006

Results From the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter

Antoine Da Costa MD, PhD*, Jérôme Thévenin MD, Frédéric Roche MD, PhD, Cécile Romeyer-Bouchard MD, Loucif Abdellaoui MD, Marc Messier PhD, Lucien Denis MD, Emmanuel Faure MD, Régis Gonthier MD, Georges Kruszynski MD, J. Marie Pages MD, Serge Bonijoly MD, Dominique Lamaison MD, Pascal Defaye MD, J. Claude Barthélemy MD, PhD, Thierry Gouttard MD, Karl Isaaz MD, FESC, for the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial of Atrial Flutter Investigators

From the Division of Cardiology (A.D.C., J.T., C.R.-B., K.I.), Department of Physiology (F.R., J.C.B.), University Jean Monnet in Saint-Etienne, Saint-Etienne, France; Division of Cardiology, Firminy Hospital, Firminy, France (L.A.); Bakken Research Center, Maastricht, Netherlands (M.M.); Division of Cardiology, Saint-Chamond Hospital, Saint-Chamond, France (L.D.); Division of Cardiology, Valence Hospital, Valence, France (E.F.); Department of Medicine for the Elderly, La Charité Hospital, Saint-Etienne, France (R.G.); Division of Cardiology, Feurs Hospital, Feurs, France (G.K.); Division of Cardiology, Montbrison Hospital, Montbrison, France (J.M.P.); Division of Cardiology, Annonay Hospital, Annonay, France (S.B., T.G.); Division of Cardiology, University of Clermont-Ferrand, Clermont-Ferrand, France (D.L.); and Division of Cardiology, University of Grenoble, Hôpital Nord, Grenoble, France (P.D.).

* To whom correspondence should be addressed. E-mail: dakosta{at}aol.com.

Background--There is no published randomized study comparing amiodarone therapy and radiofrequency catheter ablation (RFA) after only 1 episode of symptomatic atrial flutter (AFL). The aim of the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial of Atrial Flutter was 2-fold: (1) to prospectively compare first-line RFA (group I) versus cardioversion and amiodarone therapy (group II) after only 1 AFL episode; and (2) to determine the impact of both treatments on the long-term risk of subsequent atrial fibrillation (AF).

Methods and Results--From October 2002 to February 2006, 104 patients (aged 78±5 years; 20 women) with AFL were included, with 52 patients in group I and 52 patients in group II. The cumulative risk of AFL or AF was interpreted with the use of Kaplan-Meier curves and compared by the log-rank test. Clinical presentation, echocardiographic data, and follow-up were as follows: age (78.5±5 versus 78±5 years), history of AF (27% versus 21.6%); structural heart disease (58% versus 65%), left ventricular ejection fraction (56±14% versus 54.5±14%), left atrial size (43±7 versus 43±6 mm), mean follow-up (13±6 versus 13±6 months; P=NS), recurrence of AFL (3.8% versus 29.5%; P<0.0001), and occurrence of significant AF beyond 10 minutes (25% versus 18%; P=0.3). Five complications (10%) were noted in group II (sick sinus syndrome in 2, hyperthyroidism in 1, and hypothyroidism in 2) and none in group I (0%) (P=0.03).

Conclusions--RFA should be considered a first-line therapy even after the first episode of symptomatic AFL. There is a better long-term success rate, the same risk of subsequent AF, and fewer secondary effects.


Key words: ablation • arrhythmia • atrial flutter • catheter ablation


Related Article:

Issue Highlights
Circulation 2006 114: 1669. [Extract] [Full Text]



This article has been cited by other articles:


Home page
HeartHome page
C. Blomstrom-Lundqvist
Drug treatment of supraventricular tachycardia
Heart, November 1, 2009; 95(21): 1803 - 1807.
[Full Text] [PDF]


Home page
EuropaceHome page
G. Barbato, V. Carinci, C. Tomasi, V. Frassineti, M. Margheri, and G. Di Pasquale
Is electrocardiography a reliable tool for identifying patients with isthmus-dependent atrial flutter?
Europace, August 1, 2009; 11(8): 1071 - 1076.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
A. Da Costa
Catheter ablation procedures: role of nation-wide registries
Europace, February 1, 2009; 11(2): 133 - 134.
[Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
J.#x.;n. Farré, H. J.J. Wellens, J.#x. M. Rubio, and J. Benezet
CHAPTER 28 Supraventricular Tachycardias
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
D. W. C. Ng, G. T. Altemose, Q. Wu, K. Srivathsan, and L. R. P. Scott
Typical Atrial Flutter as a Risk Factor for the Development of Atrial Fibrillation in Patients Without Otherwise Demonstrable Atrial Tachyarrhythmias
Mayo Clin. Proc., June 1, 2008; 83(6): 646 - 650.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. M. Scheinman and E. Keung
The Year in Review of Clinical Cardiac Electrophysiology
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2075 - 2081.
[Full Text] [PDF]


Home page
JAMAHome page
P. Vassallo and R. G. Trohman
Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
JAMA, September 19, 2007; 298(11): 1312 - 1322.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Catheter Ablation vs. Amiodarone for First Atrial Flutter in Elders
Journal Watch Cardiology, November 14, 2006; 2006(1114): 4 - 4.
[Full Text]


Home page
CirculationHome page
D. G. Wyse
Transvenous Radiofrequency Catheter Ablation for Atrial Flutter and Atrial Fibrillation: The End of the Beginning?
Circulation, October 17, 2006; 114(16): 1670 - 1672.
[Full Text] [PDF]